InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Strengthens Management Team with Strategic Appointments
September 28, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has strengthened its leadership team with the appointments of Mark S. Berger, M.D. to the newly-created position of chief medical officer and Hemant Kumar, Ph.D., CPM, EMBA to the newly-created position of […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in Two Upcoming Investor Conferences
September 20, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, will be a featured presenter in both the CEO Roadshow Webinar series and the Benzinga Healthcare Small Cap Conference.Genprex president and CEO Rodney Varner will be presenting at both events, with the presentations focused on the company’s […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in CEO Roadshow Webinar Series
July 20, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its president and CEO Rodney Varner will be participating in a webinar series with CEO Roadshow. The CEO Roadshow features small- and mid-cap stocks on the verge of a breakout or having other […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Achieves Key Milestones for Its Acclaim-1 Clinical Trial
June 23, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has reviewed and confirmed all comments have been addressed regarding the company’s protocol for the Acclaim-1 clinical trial. The open-label, multi-center Phase 1/2 clinical trial will […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present in Noble Capital Markets’ Virtual Roadshow
May 19, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will participate in Noble Capital Markets’ Virtual Roadshow Series, presented by Channelchek on May 20, 2021. The virtual roadshow will feature a corporate presentation from Genprex’s president and CEO Rodney Varner followed […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for May Investor Conferences
May 10, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will participate in a number of virtual conferences for the month of May, including the Diamond Equity Emerging Growth Invitational, the Benzinga Small Cap Conference and the CEO Roadshow Webinar Series. Genprex’s […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Expansion of World-Class IP Portfolio
May 6, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has entered into an amendment to a May 2020 license agreement with a major cancer research center in Houston, Texas, to grant to Genprex an exclusive worldwide license to an additional portfolio […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Centralized IRB Approval for Acclaim-1 Clinical Trial
May 5, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its receipt of centralized Institutional Review Board (“IRB”) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung cancer (“NSCLC”). Acclaim-1 is an open-label, multi-center Phase 1/2 clinical […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Acclaim-2 Clinical Trial
May 4, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). An open-label, multicenter Phase 1/2 clinical trial, Acclaim-2 combines Genprex’s lead drug […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in CEO Roadshow Webinar Series
April 21, 2021
Genprex (NASDAQ: GNPX) CEO Rodney Varner will be a regular featured guest in an upcoming webinar series with CEO Roadshow. The series creates a weekly opportunity for Varner to provide weekly updates and highlight GNPX’s gene therapy pipeline in cancer and diabetes; in addition, Varner will answer questions following each week’s presentation. The webinar series […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives License of Year Award for Advances Made with Gene Therapy Program in Diabetes
April 20, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, was named the recipient of the first-ever License of the Year award presented from the University of Pittsburgh Innovation Institute (“UPII”). The award honors advances made with GNPX’s license from University of Pittsburgh toward progressing the development […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Presentation of Positive REQORSA(TM) Preclinical Data to Audience of World’s Leading Cancer Researchers
April 12, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (“NSCLC”). According to the update, collaborators also presented […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Virtual Cell & Gene Meeting on the Mediterranean
April 5, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, has announced that its COO and Executive VP, Michael Redman, will present at the annual Cell & Gene Meeting on the Mediterranean. The event is slated to take place virtually from April 6-9, 2021, with company […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Preclinical Data Highlighting Potential for TUSC2 Immunogene Therapy to Be Featured at AACR 21
March 30, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that preclinical data of its TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies, as well as in combination with targeted therapies to overcome resistance to osimertinib, for the treatment of non-small cell […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Spring 2021 Oncology Investor Conference
March 24, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will present at the Spring 2021 Oncology Investor Conference taking place virtually March 29 – April 2, 2021. According to the update, Genprex’s president and CEO, Rodney Varner, will deliver a virtual […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for March Investor Conferences
March 1, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its plans to participate in two virtual investor conferences in the month of March. These include the Sachs 14th Annual European Life Sciences CEO Forum taking place March 10-12, as well as the 33rd […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Forms Clinical Advisory Board, Announces $25M Registered Direct Offering
February 9, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it has created a Clinical Advisory Board (“CAB”). The company has named world-renowned medical and clinical experts as the board’s first members. The purpose of the board is to provide expert guidance for Genprex’s […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Joins Millions to Recognize World Cancer Day
February 4, 2021
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it joins with millions of healthcare advocates around the world in support of World Cancer Day. The designation seeks to raise awareness, elevate public understanding of the global cancer burden, promote greater equity and ensure that cancer control […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Issues Shareholder Letter, Corporate Update
February 1, 2021
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has issued a shareholder letter and corporate update outlining its developments and initiatives for 2020 and anticipated milestones for 2021 and beyond. “We achieved many significant milestones in 2020 that have set the stage for a transformational 2021,” stated Rodney Varner, […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO to Present at Upcoming Virtual Investor Conference Small and Microcap Showcase
January 27, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s president and CEO Rodney Varner will present at the Virtual Investor Conference Small and Microcap Showcase at 11 AM ET on February 4, 2021. Varner will be providing a virtual company […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present Trailblazing Gene Therapies at the MoneyShow Accredited Investors Virtual Expo
January 21, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s President and Chief Executive Officer, Rodney Varner, will provide a company overview at the MoneyShow Accredited Investors Virtual Expo taking place virtually January 26-28, 2021. GNPX’s presentation will shine a light […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present at NobleCon17
January 14, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it will present at the upcoming NobleCon17, scheduled for Jan. 19–20, 2021. The virtual event is Noble Capital Markets’ annual investor conference. GNPX’s presentation will include a company overview and address the company’s recent […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Passes Final Release Tests for Manufacturing Run of Proprietary Immunogene Therapy Treatment
January 13, 2021
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced that it has achieved a significant milestone for its REQORSA(TM) Immunogene Therapy. The company has met all specifications and passed all final release tests for its initial scaled-up, clinical-grade manufacturing run of REQORSA(TM) immunogene therapy. This […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures $12M in Registered Direct Offering
December 28, 2020
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced the closing of its registered direct offering of 3,116,884 shares of its common stock with a single health care-dedicated institutional investor. Genprex secured gross proceeds of $12 million, before deducting commissions and estimated expenses, with the offering priced at-the-market […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters into Estimated $12-Million Securities Purchase Agreement
December 23, 2020
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor. The agreement outlines the purchase and sale of 3,116,884 shares of Genprex common stock; the purchase price of those shares will be $3.85 […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Reaches Another Significant Milestone with Scaled-up Production of Clinical-Grade REQORSA(TM)
December 22, 2020
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced its completion of the manufacturing scale-up of REQORSA(TM) immunogene therapy. Subject to satisfactory completion of final testing currently underway, the clinical-grade production is intended to supply Genprex’s upcoming Acclaim-1 and Acclaim-2 clinical trials for the treatment of non-small cell […]
Genprex Inc. (NASDAQ: GNPX) Featured in Virtual Coverage of Benzinga’s Global Small Cap Conference
December 9, 2020
Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Finalizes Technology Transfer of Manufacturing Process for Novel Gene Therapy
December 8, 2020
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has reached a significant milestone. The company successfully completed the technology transfer of its manufacturing process for the production of its lead candidate for immunogene therapy, REQORSA(TM). The transfer was made from the major cancer research institution […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present Overview, Clinical Trial Update at Upcoming Benzinga Conference
December 3, 2020
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will present at the Benzinga Global Small Cap Conference taking place virtually on Dec. 8-9, 2020. Genprex’s president and CEO, Rodney Varner, will deliver a company overview that includes recent progress the company has made on its […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Upcoming Acclaim-1 Clinical Trial
December 1, 2020
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, on Monday announced its commencement of clinical trial site recruitment for its upcoming Acclaim-1 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). The company’s timing of patient recruitment and enrollment keeps it on track for its Acclaim-1 clinical […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Diamond Equity Research Emerging Growth Invitational
November 24, 2020
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will participate at the Diamond Equity Research Emerging Growth Invitational taking place virtually on Dec. 1, 2020. According to the update, Genprex’s executive vice president and COO, Michael Redman, will virtually deliver […]
InvestorNewsBreaks – Benzinga Launches Global Small Cap Conference Series; First Event Slated for December
November 11, 2020
Benzinga, an innovative financial media outlet that has developed a strong reputation for hosting unique and well-regarded events, has announced a new investor conference series: the Benzinga Global Small Cap Conference. The first event in the series is scheduled for Dec. 7, 2020, and will be completely online. This new event series is specifically designed […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in Life Sciences Summit Panel
November 11, 2020
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its senior vice president of intellectual property and licensing, Thomas Gallagher, will participate at the annual NYC-based Life Sciences Summit. Gallagher will take part in a panel discussion titled, “Show Me the Money: […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Expands Scientific Advisory Board with Strategic Appointment
November 10, 2020
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the addition of George K. Gittes, MD to its Scientific Advisory Board (“SAB”). According to the update, Dr. Gittes is the inventor of GNPX’s licensed diabetes gene therapy technology that is currently in development […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Launch of New Branding for Upcoming Combination Clinical Trials
October 30, 2020
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced the launch of new branding for its upcoming oncology clinical trials. The trials combine Genprex’s lead drug candidate, REQORSA(TM) (quaratusugene ozeplasmid), with AstraZeneca’s Tagrisso(R) (osimertinib), which received U.S. Food and Drug Administration (“FDA”) Fast Track Designation […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Conditional FDA Acceptance of Proprietary Name for Lead Drug Candidate
October 29, 2020
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has received conditional FDA acceptance of the proprietary name REQORSA(TM), its lead drug candidate for treatment of non-small cell lung cancer. The drug candidate was known previously by the laboratory designation GPX-001. The approval of the new […]
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints Eric Chapdelaine to Senior Manufacturing Team
October 26, 2020
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced the promotion of Eric Chapdelaine to vice president of manufacturing. According to the update, Chapdelaine’s promotion is a result of the company’s achievement of key manufacturing milestones to support upcoming clinical trials of its lead drug […]